Vitamin-mediated Cell Delivery of Oligonucleotides

23-May-2014 - Link Technologies Ltd has announced the availability of a novel vitamin modifier, which has shown in initial tests to have the potential of improving cell delivery of oligonucleotides. The new reagent, 5’-Niacin-CE Phosphoramidite, is easily incorporated during solid phase oligo synthesis. The ...

Link Technologies Announces Partnership with American International Chemical

AIC to distribute Link’s specialist oligonucleotide modifiers in North America

25-May-2012 - Link Technologies Ltd has announced that it will partner with American International Chemical (AIC) to distribute Link-branded products in North America. AIC will offer a sub-set of Link’s specialist oligonucleotide reagents, focusing on the bulk market for oligonucleotide modifiers. The ...

Link Technologies secures exclusive license for ultra sensitive diagnostic probes

Deal marks the start of ongoing collaboration between Link and The University of Manchester

01-Dec-2009 - Link Technologies Ltd has announced an exclusive license deal with The University of Manchester Intellectual Property Limited (UMIP). Under the terms of the license for the University’s “exciplex” technology, Link will manufacture and sell highly sensitive exciplex-based diagnostic reagents ...

Link Technologies inks exclusive license to Agilent Technologies’ TC RNA Monomers

20-May-2009 - Link Technologies Limited announced the commercialisation and launch of TC RNA Monomers under exclusive license with Agilent Technologies Inc. Under the terms of the agreement Link will manufacture and sell the four RNA monomer phosphoramidite reagents for use in research. No financial details of ...

Link Technologies Awarded ISO Quality Certification and Opens New Kilo Labs

12-Mar-2008 - Link Technologies Limited announced its accreditation to the worldwide recognised quality standard ISO 9001:2000. This has been achieved in parallel with the construction of several new multi-purpose kilo-scale manufacturing laboratories at its Bellshill site. Chairman of Link Technologies, Dr ...

PNA Monomers: A Licence to Deal

Link Technologies to manufacture and sell PNA Monomers following deal with PNA Inventor Group

26-Jun-2007 - Link Technologies Limited and the PNA Inventor Group have entered into a non-exclusive licence agreement to allow Link Technologies to manufacture and sell monomers for peptide nucleic acid (PNA) synthesis worldwide under the PNA Inventor Group's patents. Financial details have not been ...

Michael McLean Appointed as Chairman of Link Technologies Ltd

14-May-2007 - Link Technologies Limited, manufacturer of oligonucleotide synthesis reagents, has appointed former President of Avecia Biotechnology Inc, Dr Michael McLean, as Chairman to lead them through an exciting period of change and expansion. The Company is actively seeking business partners to ...